Integrated network pharmacology and molecular docking elucidate that the 26 potential hypoglycemic compounds in MLSG may exert anti-type 2 diabetes mellitus (T2DM) effects by synergistically regulating core targets (STAT3, AKT1, PIK3CA, EGFR, and MAPK1) and modulating the AGE-RAGE, PI3K-Akt, and HIF-1 other signaling pathways. This evidence concerns the gene MAPK1 and diabetes mellitus.